Cover Image
市場調查報告書

Vascular Biogenics Ltd.的產品平台分析

Vascular Biogenics Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256062
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Vascular Biogenics Ltd.的產品平台分析 Vascular Biogenics Ltd. - Product Pipeline Review - 2015
出版日期: 2015年06月30日 內容資訊: 英文 32 Pages
簡介

Vascular Biogenics Ltd是開發免疫-發炎性疾病及癌症治療藥的生物科技企業。

本報告提供Vascular Biogenics Ltd.的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,現在暫停中的計劃等資訊。

Vascular Biogenics Ltd.的基本資料

Vascular Biogenics Ltd.概要

  • 主要資訊
  • 企業資料

Vascular Biogenics Ltd.:R&D概要

  • 主要的治療範圍

Vascular Biogenics Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Vascular Biogenics Ltd.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Vascular Biogenics Ltd.:藥物簡介

  • VB-111
  • VB-201
  • 癌症治療的第2代遺傳基因療法
  • TLR2及TLR4較量的小分子

Vascular Biogenics Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Vascular Biogenics Ltd.:最近的開發平台趨勢

Vascular Biogenics Ltd.:暫停中的計劃

Vascular Biogenics Ltd.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • CI-101
  • VB-201

Vascular Biogenics Ltd.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07228CDB

Summary

Global Markets Direct's, 'Vascular Biogenics Ltd. - Product Pipeline Review - 2015', provides an overview of the Vascular Biogenics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vascular Biogenics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vascular Biogenics Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vascular Biogenics Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vascular Biogenics Ltd.'s pipeline products

Reasons to buy

  • Evaluate Vascular Biogenics Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vascular Biogenics Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vascular Biogenics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vascular Biogenics Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vascular Biogenics Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vascular Biogenics Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vascular Biogenics Ltd. Snapshot
    • Vascular Biogenics Ltd. Overview
    • Key Information
    • Key Facts
  • Vascular Biogenics Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Vascular Biogenics Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vascular Biogenics Ltd. - Pipeline Products Glance
    • Vascular Biogenics Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Vascular Biogenics Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Vascular Biogenics Ltd. - Drug Profiles
    • VB-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VB-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Second Generation Gene Therapy for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vascular Biogenics Ltd. - Pipeline Analysis
    • Vascular Biogenics Ltd. - Pipeline Products by Target
    • Vascular Biogenics Ltd. - Pipeline Products by Route of Administration
    • Vascular Biogenics Ltd. - Pipeline Products by Molecule Type
    • Vascular Biogenics Ltd. - Pipeline Products by Mechanism of Action
  • Vascular Biogenics Ltd. - Recent Pipeline Updates
  • Vascular Biogenics Ltd. - Dormant Projects
  • Vascular Biogenics Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CI-101
      • VB-201
  • Vascular Biogenics Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vascular Biogenics Ltd., Key Information
  • Vascular Biogenics Ltd., Key Facts
  • Vascular Biogenics Ltd. - Pipeline by Indication, 2015
  • Vascular Biogenics Ltd. - Pipeline by Stage of Development, 2015
  • Vascular Biogenics Ltd. - Monotherapy Products in Pipeline, 2015
  • Vascular Biogenics Ltd. - Phase II, 2015
  • Vascular Biogenics Ltd. - Phase I, 2015
  • Vascular Biogenics Ltd. - Preclinical, 2015
  • Vascular Biogenics Ltd. - Pipeline by Target, 2015
  • Vascular Biogenics Ltd. - Pipeline by Route of Administration, 2015
  • Vascular Biogenics Ltd. - Pipeline by Molecule Type, 2015
  • Vascular Biogenics Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Vascular Biogenics Ltd. - Recent Pipeline Updates, 2015
  • Vascular Biogenics Ltd. - Dormant Developmental Projects,2015
  • Vascular Biogenics Ltd. - Discontinued Pipeline Products, 2015

List of Figures

  • Vascular Biogenics Ltd. - Pipeline by Top 10 Indication, 2015
  • Vascular Biogenics Ltd. - Pipeline by Stage of Development, 2015
  • Vascular Biogenics Ltd. - Monotherapy Products in Pipeline, 2015
  • Vascular Biogenics Ltd. - Pipeline by Top 10 Target, 2015
  • Vascular Biogenics Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Vascular Biogenics Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Vascular Biogenics Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top